149 related articles for article (PubMed ID: 14605764)
1. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
Dionne SO; Myers CE; Smith MH; Lake DF
Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
[TBL] [Abstract][Full Text] [Related]
2. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.
Castilleja A; Carter D; Efferson CL; Ward NE; Kawano K; Fisk B; Kudelka AP; Gershenson DM; Murray JL; O'Brian CA; Ioannides CG
J Immunol; 2002 Oct; 169(7):3545-54. PubMed ID: 12244144
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of CTL against gp100 altered peptide ligands.
Dionne SO; Smith MH; Marincola FM; Lake DF
Cancer Immunol Immunother; 2003 Apr; 52(4):199-206. PubMed ID: 12669244
[TBL] [Abstract][Full Text] [Related]
4. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Fisk B; Blevins TL; Wharton JT; Ioannides CG
J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
[TBL] [Abstract][Full Text] [Related]
5. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
6. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
7. Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2.
Myers CE; Dionne SO; Shakalya K; Mahadevan D; Smith MH; Lake DF
Hum Immunol; 2008 Jan; 69(1):24-31. PubMed ID: 18295672
[TBL] [Abstract][Full Text] [Related]
8. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
10. Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen.
Li F; Yang D; Wang Y; Liu B; Deng Y; Wang L; Shang X; Tong W; Ni B; Wu Y
Cancer Immunol Immunother; 2009 Dec; 58(12):2039-49. PubMed ID: 19430788
[TBL] [Abstract][Full Text] [Related]
11. An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity.
Tang Y; Lin Z; Ni B; Wei J; Han J; Wang H; Wu Y
Cancer Immunol Immunother; 2007 Mar; 56(3):319-29. PubMed ID: 16906394
[TBL] [Abstract][Full Text] [Related]
12. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
[TBL] [Abstract][Full Text] [Related]
13. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of antiviral and allogeneic activity of a human public CTL clonotype by a single altered peptide ligand: implications for allograft rejection.
Ely LK; Green KJ; Beddoe T; Clements CS; Miles JJ; Bottomley SP; Zernich D; Kjer-Nielsen L; Purcell AW; McCluskey J; Rossjohn J; Burrows SR
J Immunol; 2005 May; 174(9):5593-601. PubMed ID: 15843558
[TBL] [Abstract][Full Text] [Related]
16. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes.
Tanaka Y; Amos KD; Joo HG; Eberlein TJ; Goedegebuure PS
Int J Cancer; 2001 Nov; 94(4):540-4. PubMed ID: 11745441
[TBL] [Abstract][Full Text] [Related]
17. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
19. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.
Lekka E; Gritzapis AD; Perez SA; Tsavaris N; Missitzis I; Mamalaki A; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2010 May; 59(5):715-27. PubMed ID: 19904532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
